Can-Fite BioPharma (NYSE:CANF) Stock Rating Lowered by D Boral Capital

Can-Fite BioPharma (NYSE:CANF) was downgraded by stock analysts at D Boral Capital from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.

CANF has been the subject of a number of other research reports. Zacks Research raised shares of Can-Fite BioPharma to a “hold” rating in a research note on Thursday, November 6th. D. Boral Capital cut their price target on shares of Can-Fite BioPharma from $11.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.50 price objective on shares of Can-Fite BioPharma in a report on Tuesday, November 4th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Can-Fite BioPharma has a consensus rating of “Moderate Buy” and an average target price of $3.25.

Can-Fite BioPharma Stock Up 18.6%

NYSE CANF opened at $0.21 on Wednesday. The stock’s 50-day simple moving average is $0.35 and its two-hundred day simple moving average is $0.64. Can-Fite BioPharma has a twelve month low of $0.17 and a twelve month high of $2.33. The company has a market capitalization of $5.60 million, a price-to-earnings ratio of -0.12 and a beta of 0.98.

Shares of Can-Fite BioPharma are scheduled to reverse split before the market opens on Monday, January 5th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, January 4th.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers boosted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 38,268 shares of the company’s stock after purchasing an additional 11,388 shares during the period. Rhumbline Advisers owned about 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).